ZyversaREV_cmyk.jpg
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco
18. Dezember 2024 07:55 ET | ZyVersa Therapeutics
ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
14. November 2024 08:10 ET | ZyVersa Therapeutics
ZyVersa announces progress toward achieving key near-term development milestones and Q3-2024 financials.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
05. November 2024 07:00 ET | ZyVersa Therapeutics
Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
29. Oktober 2024 07:57 ET | ZyVersa Therapeutics
Obesity treatment needs to go beyond weight loss and address the damaging inflammation leading to life-altering comorbidities.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
22. Oktober 2024 07:57 ET | ZyVersa Therapeutics
Newly published data show that obesity leads to progressive brain inflammation that worsens with prolonged obesity and increased age.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
15. Oktober 2024 07:50 ET | ZyVersa Therapeutics
ZyVersa discusses trend toward add-on therapy for obesity to address metabolic complications and the role of inflammasome inhibitors on Big Biz Show.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
07. Oktober 2024 07:55 ET | ZyVersa Therapeutics
ZyVersa Therapeutics forms new obesity, metabolic and inflammatory disease Scientific Advisory Board.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
29. Juli 2024 07:45 ET | ZyVersa Therapeutics
Plasma levels of inflammasome ASC show promise as a biomarker of early cognitive decline in older adults.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
25. Juli 2024 07:57 ET | ZyVersa Therapeutics
WESTON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
18. Juli 2024 11:18 ET | ZyVersa Therapeutics
Inflammasome ASC Inhibitor IC 100 Reduced Inflammation and Restored Retinal Structure and Function in Retinopathy of Prematurity Animal Model